Prosecution Insights
Last updated: August 14, 2026
Application No. 18/338,011

METHOD, SYSTEM, AND COMPOSITION FOR COLORING DENTAL CERAMICS

Non-Final OA §103§112
Filed
Jun 20, 2023
Priority
Jun 21, 2022 — provisional 63/353,932
Examiner
HOLLOMAN, NANNETTE
Art Unit
1732
Tech Center
1700 — Chemical & Materials Engineering
Assignee
James R. Glidewell Dental Ceramics Inc.
OA Round
1 (Non-Final)
60%
Grant Probability
Moderate
1-2
OA Rounds
0m
Est. Remaining
84%
With Interview

Examiner Intelligence

Grants 60% of resolved cases
60%
Career Allowance Rate
478 granted / 790 resolved
-4.5% vs TC avg
Strong +23% interview lift
Without
With
+23.1%
Interview Lift
resolved cases with interview
Typical timeline
3y 0m
Avg Prosecution
20 currently pending
Career history
811
Total Applications
across all art units

Statute-Specific Performance

§101
1.7%
-38.3% vs TC avg
§103
55.8%
+15.8% vs TC avg
§102
17.4%
-22.6% vs TC avg
§112
18.9%
-21.1% vs TC avg
Black line = Tech Center average estimate • Based on career data from 790 resolved cases

Office Action

§103 §112
DETAILED ACTION Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . Response to Election/Restrictions Applicant’s election without traverse of Group I, claims 1-16 in the reply filed on 03/18/2026 is acknowledged. Claims 17-20 are withdrawn from further consideration pursuant to 37 CFR 1.142(b) as being drawn to a nonelected invention, there being no allowable generic or linking claim. Election was made without traverse in the reply filed on 03/18/2026. Claim Rejections - 35 USC § 112 The following is a quotation of 35 U.S.C. 112(b): (b) CONCLUSION.—The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the inventor or a joint inventor regards as the invention. The following is a quotation of 35 U.S.C. 112 (pre-AIA ), second paragraph: The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the applicant regards as his invention. Claims 3-5 are rejected under 35 U.S.C. 112(b) or 35 U.S.C. 112 (pre-AIA ), second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which the inventor or a joint inventor (or for applications subject to pre-AIA 35 U.S.C. 112, the applicant), regards as the invention. Claims 4 and 5 contain phrases within a parenthesis and it is not clear if those phrases are limitations to the claims. Claim 3 contains the trademark/trade name VITA A1-D4® Classical shades. Where a trademark or trade name is used in a claim as a limitation to identify or describe a particular material or product, the claim does not comply with the requirements of 35 U.S.C. 112(b) or 35 U.S.C. 112 (pre-AIA ), second paragraph. See Ex parte Simpson, 218 USPQ 1020 (Bd. App. 1982). The claim scope is uncertain since the trademark or trade name cannot be used properly to identify any particular material or product. A trademark or trade name is used to identify a source of goods, and not the goods themselves. Thus, a trademark or trade name does not identify or describe the goods associated with the trademark or trade name. In the present case, the trademark/trade name is used to identify/describe a particular shade or color and, accordingly, the identification/description is indefinite. Claim Rejections - 35 USC § 103 In the event the determination of the status of the application as subject to AIA 35 U.S.C. 102 and 103 (or as subject to pre-AIA 35 U.S.C. 102 and 103) is incorrect, any correction of the statutory basis (i.e., changing from AIA to pre-AIA ) for the rejection will not be considered a new ground of rejection if the prior art relied upon, and the rationale supporting the rejection, would be the same under either status. The following is a quotation of 35 U.S.C. 103 which forms the basis for all obviousness rejections set forth in this Office action: A patent for a claimed invention may not be obtained, notwithstanding that the claimed invention is not identically disclosed as set forth in section 102, if the differences between the claimed invention and the prior art are such that the claimed invention as a whole would have been obvious before the effective filing date of the claimed invention to a person having ordinary skill in the art to which the claimed invention pertains. Patentability shall not be negated by the manner in which the invention was made. The factual inquiries for establishing a background for determining obviousness under 35 U.S.C. 103 are summarized as follows: 1. Determining the scope and contents of the prior art. 2. Ascertaining the differences between the prior art and the claims at issue. 3. Resolving the level of ordinary skill in the pertinent art. 4. Considering objective evidence present in the application indicating obviousness or nonobviousness. This application currently names joint inventors. In considering patentability of the claims the examiner presumes that the subject matter of the various claims was commonly owned as of the effective filing date of the claimed invention(s) absent any evidence to the contrary. Applicant is advised of the obligation under 37 CFR 1.56 to point out the inventor and effective filing dates of each claim that was not commonly owned as of the effective filing date of the later invention in order for the examiner to consider the applicability of 35 U.S.C. 102(b)(2)(C) for any potential 35 U.S.C. 102(a)(2) prior art against the later invention. Claim(s) 1-16 are rejected under 35 U.S.C. 103 as being unpatentable over Wolz (US Patent Pub. 2017/0189143) in view of Holand et al. (EP2377506 B1). Wolz et al. disclose a process for the production of dental ceramic (ABSTRACT). Wolz et al. disclose yttrium stabilized zirconium oxide, wherein the stabilized zirconium oxide interspersed with about a 3% mole fraction of yttrium oxide ([0002]). Wolz et al. disclose stabilizer solutions at a concentration of 0.001% to 30% by weight, including Fe(No3)3.9H2O, Ni(NO3)2.6H2O, Zn(no3)2.6H2O and Al(No3).9H2O ([0044], [0049],[0116], [0118] and [0119]). Wolz et al. disclose a processing a porous body with a coloring pigment solution and/or the coloring pigment stabilizer solutions and /or the chemical stabilizers so as to achieve desired colorings and/or hardness degrees and/or fissure resistance in the oxide ceramic and finally a sintering step ([0137]-[0144]). Wolz et al. disclose at wavelengths of 600nm, with a sample thickness of 30mm to 1 mm with a transmissions of 35% to 95% ([0104]). Wolz et al. differs from the instant claims insofar as they do not disclose the agent AlCl3.6H2O. Holand et al. disclose sintered ceramic material comprising AlCl3.6H2O mixed with antifoaming agents including alkyl polyalkylene glycol ethers, which meets the limitation of wetting agent of instant claim 1 ([0053]). It is obvious to replace one component for another equivalent component if it is recognized in the art that two components are equivalent and is not based on the Applicant disclosure. It is also prima facie obviousness to select a known material based on its suitability for its intended use. Also, established precedent holds that it is generally obvious to add known ingredients to known compositions with the expectation of obtaining their known function. See MPEP 2144.06. It would have been obvious to one of ordinary skill in the art to have used AlCl3.6H2O in the compositions of the primary reference based on the prior art's recognition that such species are equivalent in function, as supported by cited precedent. Conclusion Any inquiry concerning this communication or earlier communications from the examiner should be directed to NANNETTE HOLLOMAN whose telephone number is (571)270-5231. The examiner can normally be reached Monday-Friday 9am-6pm. Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Sahana S. Kaup can be reached at 571-272-6897. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /NANNETTE HOLLOMAN/Primary Examiner, Art Unit 1612
Read full office action

Prosecution Timeline

Jun 20, 2023
Application Filed
Jul 21, 2026
Non-Final Rejection mailed — §103, §112 (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12702648
TELODENDRIMER NANOCARRIERS FOR MONOMERIC AMPHOTERICIN B DELIVERY
2y 6m to grant Granted Aug 11, 2026
Patent 12691065
LIPOSOME FORMULATIONS FOR TREATMENT OF CANCERS AND DRUG RESISTANCE OF CANCERS
3y 8m to grant Granted Jul 28, 2026
Patent 12691048
TOPICAL COMPOSITION
3y 2m to grant Granted Jul 28, 2026
Patent 12685702
SUNSCREEN COMPOSITION CONTAINING BIODEGRADABLE ANTIMICROBIAL POLYMER NANOPARTICLES AS ULTRAVIOLET FILTER
3y 7m to grant Granted Jul 21, 2026
Patent 12685710
A FORMULATION FOR AN EFFECTIVE ORAL ADMINISTRATION OF CICLOPIROX WITH NO ADVERSAL GASTROINTESTINAL TOXICITY
2y 1m to grant Granted Jul 21, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.
Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

1-2
Expected OA Rounds
60%
Grant Probability
84%
With Interview (+23.1%)
3y 0m (~0m remaining)
Median Time to Grant
Low
PTA Risk
Based on 790 resolved cases by this examiner. Grant probability derived from career allowance rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month